Latest News
Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018
Cytokinetics is currently conducting a Phase 2 clinical trial of CK-2127107 – now referred to by the generic name, reldesemtiv – which is designed to assess the investigational agent’s effect […]
Read More ›Cure SMA Receives Generous Gift
Cure SMA is extremely pleased to announce a generous $620,000 gift has been made to the organization. The donation was made anonymously in honor of William N. Kanehann. Billy had […]
Read More ›Biogen Releases Statement on CHERISH Data and Plans for New Clinical Research
Biogen has provided the following community statement on the final results from CHERISH, a Phase 3 study of SPINRAZA. Dear Members of the SMA community, This past December marked one […]
Read More ›Additional Funding for SMA Care Centers Announced
Cure SMA is pleased to announce the second round of grants from $450,000 in funding, awarded to a total of 9 sites to help increase capacity at SMA treatment centers […]
Read More ›Cure SMA Announces Local Educational Symposiums in 16 US Locations
Cure SMA is pleased to announce a slate of one-day local symposiums, beginning late spring and continuing into fall 2018. The symposiums will be held in 16 locations across 15 […]
Read More ›Winter 2018 Compass Now Available Online
The winter 2018 issue of Compass is now available online. This issue covers Cure SMA’s community survey, and reviews how data is used to improve research, care and coverage in […]
Read More ›